Ioannidis and Garber describe personalised cost-effectiveness for treatments

John Ioannidis and Alan Garber, both from Stanford, have just published a new and interesting article in PLoS Medicine on individualised cost-effectiveness analysis. They think (and I agree) that knowing that it costs $8.60 to get 20 extra days without the flu is worthwhile. Especially when another example says that people over 45 with knee … Continue reading Ioannidis and Garber describe personalised cost-effectiveness for treatments

Ioannidis strikes again

“The need to consider the wider agenda in systematic reviews and meta-analysis: breadth, timing, and depth of the evidence.” Ioannidis and colleague are at it once again, looking at the quality of evidence that gives rise to the approval and eventual widespread use of clinical pharmaceuticals. In this case, they show that a common cancer … Continue reading Ioannidis strikes again